Won't be cheap? He doesn't have much leverage to bargain with. Here comes the clue train! Next stop is YOU! PPS has dropped to around 20% of its value when it was approved last year. Disappointing sales, no filings mentioned for other markets, no mention of additional commitment from SNY. Al has sunk alot of money into this and has no flowery revenue reports to show for it. He has very little to support a high price aside from his pride & greed which doesn't work well at the negotiation table if he has nothing else to back it up. SNY or any BP doesn't give money away to be nice guys, if the drug doesn't produce profit, they aren't interested. You see the leverage is on SNY's side if they even are interested in a buy out, but what supports that theory besides maybe hemorrhaging more money for a tax write off? HA! He either sells at a loss to recoup some of the money back or ride it down all the way.
So IF was so easy for approval then why haven't they filed in any of the EU nations since FDA approval? Yeah that's what I thought
1-There is no EU agency, you have to apply to each nation to be approved to market & sell your drugs there so you comment on "EU approval" is baseless. The EMA gives recommendations but is not a regulatory body.
2-The EU nations have stricter guidelines than the FDA, they don't get involved in the entire trial phases like the FDA but they are much more regulated as a society. Heck you can't sell GMO produce there, the US even with its more relaxed standards slapped Afrezza with a black label, think the EU member nations are going to go easy on them?
3-The EU has about comparable diabetic population in the US, 33M to 29M. So let's see, if it has failed to be this "blockbuster" for over year since approval to take off here, why would it do better in region with stricter standards?
You're better off investing in oil & NG while the market is depressed, that is a given it will go up within the next year. What has MNKD done in the past 7 years?
...and it is around 1/3 of the pps since then. Discuss.
You have no basis, none, to back that up. Highest it has been in the past 3 years was around $18 and has only steadily dropped. If there was any chance for an approved drug to shoot up, it was in the first year of its debut on the drug market but the demand never materialized so hence the decline. If there was a chance for this being a good profit maker (not even a blockbuster) then it would have already happened.
Reading all these pumpers pathetic attempts to reason how it is the shorts or analysts with an agenda for the reason why the stock keeps is not gaining any traction. They refuse to address the reason why the stock keeps going lower and lower is because the drug is not selling. Sounds very shrill and empty as these are teh same reasons repeated over and over for the past few years. Very few blockbuster drugs come back as a surprise and boost a company's earnings this far out from launch. The public & doctors don't care for the extra hoops the black label requires for patients go through for the prescription. If it wasn't for that then the results would be different.